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We detected distinct plasma concentration profiles of
S100B, neuropeptide Y, and secretagogin in 3 of 191
patients enrolled in a previous study investigating
brain-tissue–related markers in the blood of patients
with atrial fibrillation. Intriguingly, 2 of these 3 patients,
both of whom were without neurological symptoms at
the time of blood sampling, were diagnosed with malig-
nant glioma (MG) approximately 1 year later. To our
knowledge, this is the first report indicating that distinct
blood biomarker profiles may be detected long before
clinical manifestation of MG.
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M
alignant gliomas (MGs), including glioblas-
toma and anaplastic astrocytoma, are the
most common primary brain tumors of
adults.1 So far, no blood biomarkers have been estab-
lished for screening and early diagnosis, differential
diagnosis, or follow-up of MG, although several poten-
tial markers have been investigated in brain tumor
patients.2,3 To our knowledge, there are no previous
reports on biochemical blood alterations preceding clini-
cal manifestation of MG. Here, we report that we unex-
pectedly detected markedly elevated plasma
concentrations of S100B, neuropeptide Y (NPY), and
secretagogin (SCGN) in 3 (Patients 1–3) of 191 patients
enrolled in a previous study investigating brain-tissue–
related markers in the blood of patients with atrial fibril-
lation (AF).4 Intriguingly, 2 of these 3 patients (Patients
1 and 2) were diagnosed with MG approximately 1 year
after blood sampling. Our observation indicates that
S100B, NPY, and SCGN could be useful as blood bio-
markers in brain tumor patients.
Patients and Methods
All 191 patients described in this report were enrolled in
a previous study investigating the value of blood bio-
markers (S100B, NPY, SCGN, matrix metalloprotease
9, brain natriuretic peptide, and brain fatty acid–
binding protein) for the detection of ischemic brain
lesions in patients with AF.4 Assessment by an experi-
enced neurologist showed that all patients were free
from major neurological deficits at the time of inclusion
in the study. Exclusion criteria included history of stroke
or neurodegenerative disease. In all patients enrolled in
the study, we repeatedly sampled peripheral blood
using EDTA-treated tubes beginning within 3 days
after hospital admission.4
Measurement of concentrations of the individual
makers was performed by Biosite and Inverness
Medical Company using a fluorescence bioassay as
described previously.4 Data were handled in a double-
blind manner and the marker blood concentrations for
all patients were disclosed to us only after the end of
the enrollment period. At data disclosure, we noted
marked elevations of S100B, NPY, and SCGN plasma
concentrations in 3 of the 191 investigated patients.
Retrospective evaluation of the clinical history of these
3 patients revealed that 2 of them (Patients 1 and 2) had
been diagnosed with MG 11 and 13 months after blood
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sampling, respectively, and had already succumbed to
the disease. For the present report, the clinical history of
all the 3 patients was reconstructed from hospital files.
In addition, Patient 3 was interviewed about his current
health status by telephone in September 2009.
To exclude the possibility that more than 2 of our
patients were diagnosed with a brain tumor, a search
for all patients of our study cohort was performed in
the databases of the Austrian Brain Tumor Registry
(ABTR) and the Austrian National Cancer Registry
(ANCR) (date of search: November 2009).5
We calculated the expected incidence of MG in a
cohort of 191 persons of the Austrian population based
on the estimated overall Austrian brain tumor incidence
from the ABTR. Standardized incidence ratios (SIRs)
were calculated a the ratio of observed/expected cases
and were expressed a percentage. Age-specific incidence
rates for individual age cohorts were obtained from the
ABTR. Annual population estimates were provided by
the ANCR. The number of expected malignant brain
tumor cases was determined by calculating the sum of
age-specific incidence rates times the corresponding age-
specific person time under risk.
Results
Patients
Patient 1. The clinical course of Patient 1 is depicted in
Fig. 1A. Patient 1 was a 64-year-old man when he was
enrolled in our study because of AF in January 2004.
Beginning January 19, 2004, 7 blood samples for the
measurement of blood biomarkers were taken over a
period of 8 days. At this time, the patient displayed no
neurological symptoms.
The patient’s prior clinical history included valvular
aortic stenosis, renal artery stenosis, coronary artery
disease, and myocardial infarction several years earlier
and arterial hypertension, noninsulin-dependent dia-
betes mellitus type II, peripheral arterial disease stage
IIa, erythrocytosis, and transient facial paresis 8 years
earlier.
The patient was re-hospitalized twice (August 2004
and November 2004) in the course of the following
months due to cardiac reasons. At both hospital stays,
he did not exhibit any neurological symptoms.
On January 4, 2005, the patient was hospitalized due
to progressive somnolence for 3 days. Neuroradiology
showed a 5.5 × 2.5 cm large tumor in the right temporal
lobe with marked perifocal edema and contrast enhance-
ment. The tumor was subtotally resected on January 25,
2005. The histological diagnosis was glioblastoma mul-
tiforme (WHO grade IV).1 The patient received oral che-
motherapy with temozolomide at a dosage of 200 mg/m2
for 1 cycle (5/28 days), which was well tolerated. In
February 2005, the patient suffered deep venous throm-
bosis of the left leg and anticoagulant therapy was
initiated. At the end of February 2005, the patient devel-
oped progressive confusion and neuroradiology showed
a significant tumor progression. The patient died on
March 26, 2005.
Fig. 1. Clinical course of patients 1 and 2. (A) Time line showing the clinical course of Patient 1 from enrollment into our study until death. Gray
bars without frame: patient admitted to hospital for cardiac reasons, no neurological symptoms; gray bar with black frame: sampling for analysis
of blood biomarkers (n ¼ 7, blood samples on different days); black bar: patient admitted to hospital due to neurological symptoms/brain
tumor; white bar with black frame: temozolomide therapy (200mg/m2 for 5 days). (B) Time line showing the clinical course of Patient 2
from enrollment into our study until death. Gray bar without frame: patient admitted to hospital for cardiac reasons, no neurological
symptoms; gray bar with black frame: blood sampling for analysis of blood biomarkers (n ¼ 13, blood samples on different days); black bar:
patient admitted to hospital due to neurological symptoms/brain tumor. AA, anaplastic astrocytoma; AF, atrial fibrillation; CCT, cranial
computer tomography; Histo, histological diagnosis; OP, neurosurgical operation; MRI, brain magnetic resonance imaging.
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Patient 2. The clinical course of Patient 2 is depicted in
Fig. 1B. Patient 2 was a 72-year-old woman when she
was enrolled in our study because of AF in February
2004. Beginning February 16, 2004, 7 blood samples
for the measurement of blood biomarkers were taken
over a period of 15 days. At this time, the patient dis-
played no neurological symptoms.
The patient’s prior clinical history included glau-
coma, cataract, uterine myoma, parotid tumor of
unknown dignity, and arterial hypertension.
The patient was re-hospitalized for 8 days in March
and April 2004 for cardiac electroversion. At this hospi-
tal stay, 6 further blood samples for determination of
blood biomarker levels were taken over a period of 6
days. During this period, the patient did not exhibit
any neurological symptoms, and she was well when
she was discharged.
On March 3, 2005, the patient suffered a grand mal
seizure and was admitted to the hospital.
Neuroradiology revealed a diffuse tumor in the thal-
amic, temporo-insular, and occipital regions, showing
contrast enhancement. Ancillary neuroradiological
investigations (positron emission tomography) were
scheduled, and the patient was discharged but was read-
mitted a few days later because of increasing disorienta-
tion and repeated falls. The tumor was not biopsied or
operated because of severe thrombocytopenia (probably
heparin-induced). There was progressive worsening of
the clinical condition with progressive neurological
symptoms, and the patient died on May 18, 2005. At
autopsy, the histological diagnosis was anaplastic astro-
cytoma (WHO grade III).1
Patient 3. Patient 3 was enrolled in our study at age 30
and was admitted to the Emergency Department of
our institution in March 2004 because of
exercise-associated syncope. At presentation to the hos-
pital, the neurological status was normal. An ECG
revealed AF and laboratory analysis showed hypokale-
mia. The patient reported that he had been previously
healthy. From March 9–11, 3 blood samples were
taken for biomarker analysis. The AF subsided after elec-
trolyte substitution, and the patient was discharged. In
July 2004, electric cardioversion was performed
because of recurrent AF. As of October 2009, the
patient still has intermittent AF but is otherwise
healthy and well. He has no neurological symptoms
and works full time in an academic profession. Brain
imaging has never been performed in Patient 3.
Patients 4–191
Of these 188 patients, 119 were men and 69 were
women. The patient age at enrollment in our study
ranged from 17.02 to 98.12 years (median 68.5 years).
At enrollment in the study, all of these 188 patients
had AF and none displayed neurological symptoms.
None of these patients was registered with a brain
tumor diagnosis in the databases of the ABTR or the
ANCR as of November 2009.
Blood Biomarkers
Plasma levels of S100B, NPY, and SCGN in all patients
included in this report are summarized in Table 1 and
Fig. 2. All 3 markers showed marked elevations in
Patients 1–3 when compared with all other patients of
our study cohort (Patients 4–191). None of the patients
in our cohort had distinct profiles of BNP, MMP9, and
BFABP blood levels (data not shown).
Estimation of Malignant Brain Tumor Incidence
The expected incidence of malignant brain tumors in our
cohort of 191 persons was 0.139 leading to an estimated
SIR of 14.39 (95% CI: 1.74–51.99).
Discussion
Here, we report markedly elevated plasma levels of
S100B, NPY, and SCGN in the peripheral blood of
3 of the 191 AF patients, 2 of whom were diagnosed
with MG 11 and 13 months after blood sampling. To
our knowledge, this is the first report of distinct blood
marker profiles preceding clinical manifestation of MG.
S100B, SCGN, and NPY are expressed in brain tissue
and in some gliomas.6–9 S100B serum concentrations in
patients diagnosed with glioma have been investigated in
some studies,10–13 whereas there seem to be no data on
NPY and SCGN blood concentrations in brain tumor
patients.
Little is known about the growth kinetics of MG
prior to diagnosis. However, clinical experience suggests
that primary MG may develop within few months.14–16
Unfortunately, in neither of our 2 MG patients described
in the present report was neuroimaging performed in the
period of blood sampling. However, blood marker levels
suggest that premalignant or early malignant disease
Table 1. Plasma concentrations of S100B, NPY, and SCGN in all patients included in our study
Brain tumor Number of blood
samples per patient
S100B (pg/mL)
(median, range)
NPY (pg/mL)
(median, range)
SCGN (pg/mL)
(median, range)
Patient 1 Yes 7 1160, 903–1266 9560, 6170–10 560 1424, 1076–1834
Patient 2 Yes 13 1843, 1393–2023 10 890, 7930–11 860 2436, 1868–3078
Patient 3 No evidence 3 977, 926–1477 7070, 6940–9619 1155, 1118–2124
Patients 4–191 (n ¼ 188) No evidence Range 1–16 (median 4) ,LOD, ,LOD–947 20, ,LOD–8200 48, ,LOD–1076
Abbreviations: LOD, level of detection; NPY, neuropeptide Y; SCGN, secretagogin. All 3 markers are markedly elevated in Patients 1–3
when compared with all other patients (Patients 4–191).
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might have been already present in both patients a long
time (11 months in Patient 1 and 13 months in Patient 2)
before clinical manifestation. It may be speculated that
the disruption of the blood–brain barrier and/or the
production of the proteins by tumor cells may have
caused the elevated marker concentrations in our
patients.
Patient 3, similar to the 2 patients, who were later
diagnosed with MG, displayed markedly elevated
blood levels of S100B, NPY, and SCGN when he pre-
sented to us with exercise-associated syncope and AF.
It is unclear what has caused the marker elevations in
this case. Perhaps brain ischemia related to the syncope-
caused release of S100B, NPY, and SCGN into the
patient’s blood. It would be interesting to perform
brain MRI to search for old ischemic lesions and to
exclude the presence of a clinically silent brain neoplasia
in this patient. However, due to ethical reasons, we
decided not to burden the patient with potential brain
disease based on our preliminary data. Anyway, the find-
ings in Patient 3 indicate that plasma-level elevations of
S100B, NPY, and SCGN may not be entirely specific for
brain tumors. Indeed, elevated plasma concentrations of
these proteins have been detected in some other dis-
eases.4,6,17–19 However, most well-established and clini-
cally useful tumor markers such as carcinoembryonic
antigen, CA 19-9, or CA125 also lack perfect specificity.
Searches in the ABTR and ANCR databases, which
record brain tumor cases nationwide in Austria,5 did
not identify any other brain tumor patient in our
cohort apart from Patients 1 and 2. Moreover, the
expected number of malignant brain tumors in an
Austrian population of 191 persons based on the esti-
mated overall Austrian brain tumor incidence from
the ABTR is 0.139. Thus, it is very unlikely that
there are undetected MG cases among our study sub-
jects. So, sensitivity for the detection of MG before
onset of clinical symptoms by measurement of
S100B, NPY, and SCGN plasma concentrations may
be high.
To summarize, our observations suggest that S100B,
NPY, and SCGN could be useful as blood biomarkers in
Fig. 2. Time course of blood biomarker concentrations. (A) Plasma concentrations of S100B in Patients 1–3 (lower panel) are markedly
higher than that in all other patients of our study cohort (Patients 4–191; upper panel). (B) Plasma concentrations of NPY in Patients 1–
3 (lower panel) are markedly higher than that in all other patients of our study cohort (Patients 4–191; upper panel). (C) Plasma
concentrations of SCGN in Patients 1–3 (lower panel) are markedly higher than that in all other patients of our study cohort (Patients
4–191; upper panel). NPY, neuropeptide Y; Pt., patient; SCGN, secretagogin.
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brain tumor patients. Further studies that include the
evaluation of sensitivity and specificity and the charac-
terization of changes in blood concentrations during
disease course and treatment are needed to establish
the clinical usability of these markers in neuro-oncology.
To this end, we have, at our center, initiated prospective
studies including patients with other brain tumors, such
as cancer metastasis and benign tumors, and sequential
blood sampling during therapy.
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